RAMSAY HEALTH CARE LIMITED (RHC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RHC

RHC - RAMSAY HEALTH CARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.71
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Founded in Sydney in 1964, Ramsay Health Care is the largest provider of private healthcare in Australia, with operations in the UK, France, Indonesia and Malaysia. The company specialises in surgery, rehabilitation and psychiatric care. It was first listed in 1997.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$39.51

24 Mar
2026

-0.290

OPEN

$40.15

-0.73%

HIGH

$40.16

860,247

LOW

$39.19

TARGET
$40.67 2.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
RHC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 3.0 137.0 xxx
DPS (cps) xxx 80.0 82.8 xxx
EPS Growth xxx - 99.2% 100.0% xxx
DPS Growth xxx 0.0% 3.4% xxx
PE Ratio xxx N/A 29.4 xxx
Dividend Yield xxx N/A 2.1% xxx
Div Pay Ratio(%) xxx 2702.7% 60.4% xxx

Dividend yield today if purchased 3 years ago: 1.26%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.99

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 40.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx3.0
DPS All xxxxxxxxxxxxxxx80.0
Sales/Revenue xxxxxxxxxxxxxxx17,801.7 M
Book Value Per Share xxxxxxxxxxxxxxx2,075.4
Net Operating Cash Flow xxxxxxxxxxxxxxx1,497.3 M
Net Profit Margin xxxxxxxxxxxxxxx0.13 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx0.14 %
Return on Invested Capital xxxxxxxxxxxxxxx0.15 %
Return on Assets xxxxxxxxxxxxxxx0.11 %
Return on Equity xxxxxxxxxxxxxxx0.48 %
Return on Total Capital xxxxxxxxxxxxxxx5.82 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx559.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx686 M
Long Term Debt xxxxxxxxxxxxxxx11,434 M
Total Debt xxxxxxxxxxxxxxx12,120 M
Goodwill - Gross xxxxxxxxxxxxxxx6,264 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx784 M
Price To Book Value xxxxxxxxxxxxxxx1.77

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx776.6 M
Capex % of Sales xxxxxxxxxxxxxxx4.36 %
Cost of Goods Sold xxxxxxxxxxxxxxx16,075 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx729 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx111 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxxxx xx xxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

02/03/2026

3

Neutral

$42.90

8.58%

UBS believes Ramsay Health Care's interim result signals a potential inflection point, with underlying domestic margins improving 40bps and market share gains aided by disruption at competitor Healthscope.

The broker expects modest margin expansion in FY26, supported by pricing to offset nursing wage inflation and the National Capital Private Hospital acquisition. It's noted the contract for the Joondalup Health Campus in Western Australia remains a drag in H2.

The analysts also highlight tougher conditions in the UK amid reduced government budget support and assumes Elysium (UK mental health services business) is being stabilised ahead of a potential sale.

UBS retains a Neutral rating given recent share price appreciation and raises its target price to $42.90 from $35.90.

FORECAST
UBS forecasts a full year FY26 dividend of 82.00 cents and EPS of 132.00 cents.
UBS forecasts a full year FY27 dividend of 103.00 cents and EPS of 157.00 cents.

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

09/03/2026

2

Overweight

$45.20

14.40%

Ramsay Health Care posted an impressive half with its revenue, earnings and profit all beating consensus, Jarden comments. 

Australia set a great tone for the result, Jarden suggests, with revenue accelerating in 2Q26 to deliver 7.9% 1H26 revenue growth.

Australian earnings margins finally grew, while UK earnings were a big beat to consensus largely from FX, which swings around to be a headwind in 2H26, commentary notes.

Sante's loss making French operations were mitigated by FX which once again highlights the attraction of decoupling Sante from the broader Ramsay Group, the report concludes.

Target rises to $45.20 from $40.60, Overweight retained.

FORECAST
Jarden forecasts a full year FY26 dividend of 85.00 cents and EPS of 134.00 cents.
Jarden forecasts a full year FY27 dividend of 95.00 cents and EPS of 149.00 cents.
Access Extra Coverage Research History >

RHC STOCK CHART

FNArena News on RHC

1
Rudi’s View: Make Today’s Crisis Your Opportunity

Mar 25 2026 - Rudi's View
2
Rudi’s View: Top Picks & Conviction Buys

Mar 19 2026 - Rudi's View
3
Weekly Ratings, Targets, Forecast Changes – 13-03-26

Mar 16 2026 - Weekly Reports
4
Rudi’s View: Post-February Conviction Calls

Mar 12 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – Mar 12, 2026

Mar 12 2026 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps